Log In
BCIQ
Print this Print this
 

AMG 176

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionMyeloid leukemia cell differentiation protein (MCL1) inhibitor
Molecular Target Myeloid leukemia cell differentiation protein (MCL1)
Mechanism of ActionMyeloid leukemia cell differentiation protein (Mcl-1) inhibitor
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat relapsed or refractory multiple myeloma (MM)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today